{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:23Z","timestamp":1790969723662,"version":"4.1.0"},"reference-count":47,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["#20177429"],"award-info":[{"award-number":["#20177429"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration Orphan Products Clinical Trials Grants Program","doi-asserted-by":"publisher","award":["R01 FD003902"],"award-info":[{"award-number":["R01 FD003902"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration Orphan Products Clinical Trials Grants Program","doi-asserted-by":"publisher","award":["R01005114"],"award-info":[{"award-number":["R01005114"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24 AR052665"],"award-info":[{"award-number":["K24 AR052665"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R03 AR064016"],"award-info":[{"award-number":["R03 AR064016"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Simon-Strauss Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>We previously reported that sequential teriparatide followed by denosumab substantially increases bone mineral density (BMD) in premenopausal idiopathic osteoporosis (PremenIOP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine whether administration of bisphosphonates after denosumab cessation is associated with stable BMD in PremenIOP<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Open-label extension study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Twenty-four PremenIOP Teriparatide-Denosumab Study participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Oral alendronate (ALN), 70\u2005mg weekly, or intravenous zoledronic acid (ZOL), 5\u2005mg once (patient choice), was administered 7 months (M) after final denosumab dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>BMD by dual-energy x-ray absorptiometry and serum C-telopeptide (CTX) q6M; Vertebral Fracture Assessment (VFA), and high-resolution peripheral quantitative computed tomography (HR-pQCT) q12\u2005M.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-four women with PremenIOP (aged 43 \u00b1 8 years), severely affected with low trauma adult fractures (range 0-12; 9 with vertebral fractures) and\/or very low BMD, had large BMD increases on sequential teriparatide-denosumab (spine: 25 \u00b1 9%; total hip: 11 \u00b1 6%). During the Bisphosphonate Extension, mean BMD and CTX changes in the entire group were small and not statistically significant at 6 or 12\u2005M.<\/jats:p>\n                  <jats:p>Women choosing ZOL (n = 6) vs ALN (n = 18) did not differ by baseline age, body mass index, fractures, BMD, or CTX. On ZOL, there were small lumbar spine BMD declines and CTX increases, particularly between 6\u2005M and 12\u2005M, while greater stability was observed on ALN.<\/jats:p>\n                  <jats:p>Changes in BMD and CTX did not differ by duration of denosumab (36\u2005M vs &amp;lt;36\u2005M) or between 20 women who remained premenopausal and 4 who transitioned into menopause. Higher pre-teriparatide CTX, likely reflecting baseline remodeling status, predicted more spine and hip bone loss. No new vertebral (clinical or vertebral fraction assessment screening) or nonvertebral fractures occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae240","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T04:49:30Z","timestamp":1712897370000},"page":"e791-e801","source":"Crossref","is-referenced-by-count":12,"title":["Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis"],"prefix":"10.1210","volume":"110","author":[{"given":"Mafo","family":"Kamanda-Kosseh","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-3406","authenticated-orcid":false,"given":"Stephanie","family":"Shiau","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Rutgers School of Public Health , Piscataway, NJ 08854 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-0717","authenticated-orcid":false,"given":"Sanchita","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Kondapalli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelisse","family":"Colon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Kil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bucovsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M","family":"Lappe","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Center, Creighton University Medical Center , Omaha, NE 68131 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stubby","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Center, Creighton University Medical Center , Omaha, NE 68131 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shane","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-5747","authenticated-orcid":false,"given":"Adi","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"10","key":"2025021815502798500_dgae240-B1","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1210\/jc.2011-1387","article-title":"Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis","volume":"96","author":"Cohen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025021815502798500_dgae240-B2","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1210\/jc.2012-2099","article-title":"Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history","volume":"97","author":"Cohen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025021815502798500_dgae240-B3","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1210\/jc.2009-0996","article-title":"Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis","volume":"94","author":"Cohen","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815502798500_dgae240-B4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00198-011-1560-y","article-title":"Premenopausal women with idiopathic low-trauma fractures and\/or low bone mineral density","volume":"23","author":"Cohen","year":"2012","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025021815502798500_dgae240-B5","doi-asserted-by":"crossref","first-page":"e3540","DOI":"10.1210\/clinem\/dgaa489","article-title":"Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase II trial","volume":"105","author":"Cohen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025021815502798500_dgae240-B6","doi-asserted-by":"crossref","first-page":"e1528","DOI":"10.1210\/clinem\/dgab850","article-title":"Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis","volume":"107","author":"Shane","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025021815502798500_dgae240-B7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025021815502798500_dgae240-B8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025021815502798500_dgae240-B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"11","key":"2025021815502798500_dgae240-B10","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1210\/jc.2015-2829","article-title":"Bone density after teriparatide discontinuation in premenopausal idiopathic osteoporosis","volume":"100","author":"Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815502798500_dgae240-B11","first-page":"5432751","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"2018","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Rep Rheumatol"},{"issue":"Suppl 8","key":"2025021815502798500_dgae240-B12","doi-asserted-by":"crossref","first-page":"S581","DOI":"10.1097\/RHU.0000000000000979","article-title":"Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases","volume":"27","author":"Anagnostis","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"2025021815502798500_dgae240-B13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-022-06610-9","article-title":"Discontinuation of denosumab in men with prostate cancer","volume":"34","author":"Solling","year":"2023","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025021815502798500_dgae240-B14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815502798500_dgae240-B15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025021815502798500_dgae240-B16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2025021815502798500_dgae240-B17","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1210\/jc.2006-1178","article-title":"Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry","volume":"91","author":"Lewiecki","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025021815502798500_dgae240-B18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bone.2007.07.007","article-title":"Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis","volume":"41","author":"Buie","year":"2007","journal-title":"Bone"},{"issue":"3","key":"2025021815502798500_dgae240-B19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bone.2010.05.034","article-title":"Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT","volume":"47","author":"Burghardt","year":"2010","journal-title":"Bone"},{"issue":"7","key":"2025021815502798500_dgae240-B20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1359\/jbmr.1999.14.7.1167","article-title":"Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus","volume":"14","author":"Hildebrand","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025021815502798500_dgae240-B21","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00198-016-3621-8","article-title":"In vivo assessment of bone structure and estimated bone strength by first- and second-generation HR-pQCT","volume":"27","author":"Agarwal","year":"2016","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025021815502798500_dgae240-B22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.medengphy.2006.11.002","article-title":"Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality","volume":"29","author":"MacNeil","year":"2007","journal-title":"Med Eng Phys"},{"key":"2025021815502798500_dgae240-B23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bone.2015.06.006","article-title":"Human trabecular bone microarchitecture can be assessed independently of density with second generation HR-pQCT","volume":"79","author":"Manske","year":"2015","journal-title":"Bone"},{"issue":"4","key":"2025021815502798500_dgae240-B24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jbmr.4780","article-title":"The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH(1-84)","volume":"38","author":"Agarwal","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025021815502798500_dgae240-B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jbmr.4739","article-title":"Teriparatide followed by denosumab in premenopausal idiopathic osteoporosis: bone microstructure and strength by HR-pQCT","volume":"38","author":"Agarwal","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025021815502798500_dgae240-B26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00223-013-9808-5","article-title":"Bone microarchitecture and estimated strength in 499 adult Danish women and men: a cross-sectional, population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure","volume":"94","author":"Hansen","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2025021815502798500_dgae240-B27","doi-asserted-by":"crossref","first-page":"e1868\u2013","DOI":"10.1210\/clinem\/dgaa654","article-title":"Long-term bone loss and deterioration of microarchitecture after gastric bypass in African American and Latina women","volume":"106","author":"Krez","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025021815502798500_dgae240-B28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bone.2011.03.755","article-title":"Quantitative characterization of subject motion in HR-pQCT images of the distal radius and tibia","volume":"48","author":"Sode","year":"2011","journal-title":"Bone"},{"issue":"2","key":"2025021815502798500_dgae240-B29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/1350-4533(95)91884-J","article-title":"Three-dimensional finite element modelling of non-invasively assessed trabecular bone structures","volume":"17","author":"Muller","year":"1995","journal-title":"Med Eng Phys"},{"issue":"1","key":"2025021815502798500_dgae240-B30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9290(95)80008-5","article-title":"A new method to determine trabecular bone elastic properties and loading using micromechanical finite-element models","volume":"28","author":"van Rietbergen","year":"1995","journal-title":"J Biomech"},{"issue":"6","key":"2025021815502798500_dgae240-B31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bone.2008.01.017","article-title":"Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method","volume":"42","author":"Macneil","year":"2008","journal-title":"Bone"},{"issue":"6","key":"2025021815502798500_dgae240-B32","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S8756-3282(02)00736-6","article-title":"Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images","volume":"30","author":"Pistoia","year":"2002","journal-title":"Bone"},{"key":"2025021815502798500_dgae240-B33","doi-asserted-by":"crossref","unstructured":"Kamanda-Kosseh M, Shiau S, Agarwal S, et al \u00a02024. Supplementary table from bisphosphonates maintain BMD after sequential teriparatide and denosumab in premenopausal women with idiopathic osteoporosis. Dryad. 10.5061\/dryad.5x69p8dbs. Date accessed 12 March 2024.","DOI":"10.1210\/clinem\/dgae240"},{"issue":"3","key":"2025021815502798500_dgae240-B34","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815502798500_dgae240-B35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"issue":"3","key":"2025021815502798500_dgae240-B36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025021815502798500_dgae240-B37","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025021815502798500_dgae240-B38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2025021815502798500_dgae240-B39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"2025021815502798500_dgae240-B40","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815502798500_dgae240-B41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"2025021815502798500_dgae240-B42","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep"},{"issue":"2","key":"2025021815502798500_dgae240-B43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","article-title":"Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025021815502798500_dgae240-B44","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025021815502798500_dgae240-B45","volume-title":"American Society for Bone and Mineral Research Annual Meeting","author":"Popp","year":"2019"},{"key":"2025021815502798500_dgae240-B46","doi-asserted-by":"crossref","first-page":"116498","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"issue":"4","key":"2025021815502798500_dgae240-B47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41981","article-title":"The effect of discontinuing denosumab in patients with rheumatoid arthritis treated with glucocorticoids","volume":"74","author":"Saag","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae240\/57451209\/dgae240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e791\/57451209\/dgae240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e791\/57451209\/dgae240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:11:09Z","timestamp":1739895069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/e791\/7644367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae240","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,12]]}}}